News
- Author:
- Andrew D. Bowser
Publish date: December 10, 2017
ATLANTA – ASH attendees got a preview of forthcoming recommendations on prevention and treatment of VTE in patients with cancer.
News
- Author:
- Andrew D. Bowser
Publish date: December 10, 2017
ATLANTA – Avapritinib was well tolerated in the phase 1 trial, and demonstrated encouraging preliminary activity.
News
- Author:
- Andrew D. Bowser
Publish date: December 9, 2017
ATLANTA – Voxelotor demonstrated consistent, sustained improvements in hemoglobin levels in adolescents with sickle cell disease in a phase 2b stud...
News
- Author:
- Andrew D. Bowser
Publish date: December 8, 2017
Undergoing more hyperbaric oxygen sessions reduced the mortality rate in a study of patients with carbon monoxide poisoning.
News
- Author:
- Andrew D. Bowser
Publish date: December 6, 2017
The ATTRACT trial results contrast with recent reports from another randomized trial, known as CAVENT.
News
- Author:
- Andrew D. Bowser
Publish date: December 6, 2017
The treatment prevented bleeding and virtually eliminated the need for exogenous factors.
News
- Author:
- Andrew D. Bowser
Publish date: November 29, 2017
Participants saw reductions of between 4 and 5 migraine and headache days per month with the drug over 12 weeks.
News
- Author:
- Andrew D. Bowser
Publish date: November 29, 2017
The findings could have implications for the development of new treatments designed to stimulate RBC production after bleeding, chemotherapy, or dr...
News
- Author:
- Andrew D. Bowser
Publish date: November 28, 2017
The results are limited and preliminary.
News
- Author:
- Andrew D. Bowser
Publish date: November 22, 2017
In patients with BRAF or RAS mutations, DFS was better in right-sided vs. left-sided tumors, while in patients with RAS and BRAF double wild type, ...
News
- Author:
- Andrew D. Bowser
Publish date: November 22, 2017
It is unlikely the drugs actually caused the increase in cancer risk.
News
- Author:
- Andrew D. Bowser
Publish date: November 22, 2017
ASH President Kenneth C. Anderson, MD, and ASH Secretary Robert A. Brodsky, MD, gave a preview of four practice-changing studies.
News
- Author:
- Andrew D. Bowser
Publish date: November 18, 2017
Patients with SCC “may need additional education and age-appropriate screening to prevent deaths from major diseases,” the authors concluded.
News
- Author:
- Andrew D. Bowser
Publish date: November 17, 2017
MSK-IMPACT is a custom targeted sequencing platform that uses exon capture and sequencing to identify point mutations, small insertions and deletio...
News
- Author:
- Andrew D. Bowser
Publish date: November 16, 2017
The benefit of rituximab “stands out, and adds to the increasing body of evidence supporting this practice for all MCL patients after ASCT, regardl...
